145 related articles for article (PubMed ID: 3122430)
21. [Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction].
Czyrski J
Wiad Lek; 1989 Apr; 42(7):450-2. PubMed ID: 2516932
[TBL] [Abstract][Full Text] [Related]
22. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
23. [Differential diagnosis: right heart infarct or anteroseptal infarct?].
Rupprecht HJ; von Olshausen K; Erbel R; Pop T; Meyer J
Z Kardiol; 1987 Aug; 76(8):517-20. PubMed ID: 2960091
[TBL] [Abstract][Full Text] [Related]
24. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
[TBL] [Abstract][Full Text] [Related]
25. Intracoronary thrombolysis with urokinase in acute myocardial infarction. Effects on reperfusion and left ventricular wall motion.
Cernigliaro C; Sansa M; Campi A; Sante Bongo A; Rossi P
G Ital Cardiol; 1982; 12(5):365-73. PubMed ID: 6759286
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of the thrombolytic efficacy of single-chain urokinase (Pro-urokinase) by heparin.
Gulba DC; Fischer K; Reil GH; Daniel WG; Lichtlen PR
Thromb Haemost; 1988 Oct; 60(2):350-1. PubMed ID: 3146150
[No Abstract] [Full Text] [Related]
27. Regional and systemic thrombolytic therapy in acute myocardial infarction.
Hastillo A; Cowley MJ
Cardiovasc Clin; 1984; 14(3):235-45. PubMed ID: 6722853
[TBL] [Abstract][Full Text] [Related]
28. [A double-blind comparative study of intracoronary administration of GE-0943 and urokinase: multicenter study].
Kambara H; Kawai C; Kajiwara N; Kammatsuse K; Nitani H; Sasayama S; Kodama K; Sato H; Nobuyoshi M; Nakashima M
Kokyu To Junkan; 1989 Jul; 37(7):749-56. PubMed ID: 2678331
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
30. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group.
Lancet; 1989 Apr; 1(8643):863-8. PubMed ID: 2564949
[TBL] [Abstract][Full Text] [Related]
31. [Time dependence of myocardial preservation after thrombolysis. Consequences for indication and procedure].
Mathey DG; Schofer J; Bleifeld W
Dtsch Med Wochenschr; 1985 Nov; 110(44):1681-5. PubMed ID: 4053994
[TBL] [Abstract][Full Text] [Related]
32. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
[TBL] [Abstract][Full Text] [Related]
33. Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.
Salvioni A; Perego GB; Marenzi G; Lauri G; Giraldi F; Grazi S; Guazzi MD
Eur Heart J; 1996 Feb; 17(2):230-6. PubMed ID: 8732376
[TBL] [Abstract][Full Text] [Related]
34. Thrombotic occlusion of the left main coronary artery during stenting: successful management with intracoronary urokinase and autoperfusion balloon.
Gambhir DS; Trehan V; Sudha R; Kaul UA; Arora R
Indian Heart J; 1996; 48(3):273-5. PubMed ID: 8755014
[No Abstract] [Full Text] [Related]
35. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro.
Onundarson PT; Haraldsson HM; Bergmann L; Francis CW; Marder VJ
Thromb Haemost; 1993 Dec; 70(6):998-1004. PubMed ID: 8165625
[TBL] [Abstract][Full Text] [Related]
37. Coronary thrombolysis for evolving myocardial infarction.
Spann JF; Sherry S
Drugs; 1984 Nov; 28(5):465-83. PubMed ID: 6391890
[TBL] [Abstract][Full Text] [Related]
38. [Platelet activation in the early phases of acute myocardial infarction].
Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
[TBL] [Abstract][Full Text] [Related]
39. Effects of patency of infarct-related coronary artery on acute outcome in acute myocardial infarction patients undergoing urokinase therapy. Collaborative Research Group on Thrombolysis.
Chin Med J (Engl); 1997 Mar; 110(3):187-90. PubMed ID: 9594337
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
